Larvol Delta - March-Biosciences-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-MB105-in-RelapsedRefractory-CD5Positive-TCell-Lymphoma

MB-105 - March Bio

https://www.globenewswire.com/news-release/2025/11/11/3185372/0/en/March-Biosciences-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-MB-105-in-Relapsed-Refractory-CD5-Positive-T-Cell-Lymphoma.html

Nov 11, 2025

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next